Myriad Genetics, Inc.
MYGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$367.4M
Close$
$-2.06
151.3% downside
Current Fair Value
151.3% downsideOvervalued by 151.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $367.40 Million |
|---|---|
| Enterprise Value | $462.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.96 |
| Beta | 1.68 |
| Outstanding Shares | 94,800,000 |
Return
| Return on Equity | -37.05% |
|---|---|
| Return on Assets | -17.62% |
| Return on Invested Capital | -18.85% |
Valuation & Multiples
| P/E Ratio | -3.26 |
|---|---|
| PEG | 3.75 |
| Price to Sales | 0.5 |
| Price to Book Ratio | 1.34 |
| Enterprise Value to Revenue | 0.57 |
| Enterprise Value to EBIT | -4.83 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$206.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$191.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4836▼ 34.24% |
|---|---|
| Total Calls | 42,800▲ 106.76% |
| Total Puts | 20,700▲ 21.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.69%▼ 131.71% |
|---|---|
| Total Invested | $517.79M▼ 0.28% |
| Investors Holding | 200▼ 5.00% |
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...